Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials

Total Page:16

File Type:pdf, Size:1020Kb

Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials Wright State University CORE Scholar Biomedical, Industrial & Human Factors Biomedical, Industrial & Human Factors Engineering Faculty Publications Engineering 7-2015 Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials Derralynn A. Hughes Derlis Gonzalez Elena A. Lukina Atul Mehta Madhulika Kabra See next page for additional authors Follow this and additional works at: https://corescholar.libraries.wright.edu/bie Part of the Biomedical Engineering and Bioengineering Commons, and the Industrial Engineering Commons Repository Citation Hughes, D. A., Gonzalez, D., Lukina, E. A., Mehta, A., Kabra, M., Elstein, D., Kisinovsky, I., Giraldo, P., Bavdekar, A., Hangartner, T. N., Wang, N., Crombez, E., & Zimran, A. (2015). Velaglucerase Alfa (VPRIV) Enzyme Replacement Therapy in Patients with Gaucher Disease: Long-Term Data from Phase III Clinical Trials. American Journal of Hematology, 90 (7), 584-591. https://corescholar.libraries.wright.edu/bie/111 This Article is brought to you for free and open access by the Biomedical, Industrial & Human Factors Engineering at CORE Scholar. It has been accepted for inclusion in Biomedical, Industrial & Human Factors Engineering Faculty Publications by an authorized administrator of CORE Scholar. For more information, please contact library- [email protected]. Authors Derralynn A. Hughes, Derlis Gonzalez, Elena A. Lukina, Atul Mehta, Madhulika Kabra, Deborah Elstein, Isaac Kisinovsky, Pilar Giraldo, Ashish Bavdekar, Thomas N. Hangartner, Nan Wang, Eric Crombez, and Ari Zimran This article is available at CORE Scholar: https://corescholar.libraries.wright.edu/bie/111 RESEARCH ARTICLE AJH Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials Derralynn A. Hughes,1,2* Derlis E. Gonzalez,3 Elena A. Lukina,4 Atul Mehta,1,2 Madhulika Kabra,5 Deborah Elstein,6 Isaac Kisinovsky,7 Pilar Giraldo,8,9 Ashish Bavdekar,10 Thomas N. Hangartner,11 Nan Wang,12 Eric Crombez,13 and Ari Zimran6 Type 1 Gaucher disease is an inherited lysosomal enzyme deficiency with variable age of symptom onset. Common presenting signs include thrombocytopenia, anemia, hepatosplenomegaly, bone abnormalities, and, additionally in children, growth failure. Fifty-seven patients aged 3–62 years at the baseline of two phase III trials for velaglucerase alfa treatment were enrolled in the single extension study. In the extension, they received every-other-week velaglucerase alfa intravenous infusions for 1.2–4.8 years at 60 U/kg, although 10 patients experienced dose reduction. No patient experienced a drug-related serious adverse event or withdrew due to an adverse event. One patient died following a convulsion that was reported as unrelated to the study drug. Only one patient tested positive for anti-velaglucerase alfa antibodies. Combining the experience of the initial phase III trials and the extension study, significant improvements were observed in the first 24 months from baseline in hematology variables, organ volumes, plasma biomarkers, and, in adults, the lumbar spine bone mineral density Z-score. Improvements were maintained over longer-term treatment. Velaglucerase alfa had a good long-term safety and tolerability profile, and patients continued to respond clinically, which is consistent with the results of the extension study to the phase I/II trial of velaglucerase alfa. EudraCT number 2008-001965-27; www.clinicaltrials.gov identifier NCT00635427. Am. J. Hematol. 90:584–591, 2015. VC 2015 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. ᭿ Introduction Gaucher disease (GD) is a rare genetic disease caused by mutations in GBA, which encodes a hydrolytic, lysosomal enzyme (glucosylceramidase). When this enzyme is deficient, the major natural glucocerebroside substrates of the enzyme accumulate in cells, notably macrophages, which are most responsible for the visceral pathophysiology in type 1 GD. Type 1 GD can present at variable ages with thrombocytopenia, anemia, hepatosple- nomegaly, bone marrow infiltration, and various focal and generalized bone abnormalities, and additionally in children, with growth failure [1,2]. Current GD-specific treatment, enzyme replacement therapy (ERT) and substrate reduction therapy, is beneficial but not curative, and so patients usually have regular continual dosing. Valuable research into disease outcomes, with and without treatment, has been conducted through Additional Supporting Information may be found in the online version of this article. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 1Department of Haematology, Royal Free Hospital, London, United Kingdom; 2Department of Haematology, University College London, London, United Kingdom; 3Instituto Privado de Hematologıa e Investigacion Clınica – IPHIC, Asuncion, Paraguay; 4Department of Orphan Diseases, Hematology Research Center, Moscow, Rus- sia; 5Pediatrics Department, All India Institute of Medical Sciences, New Delhi, India; 6Gaucher Clinic, Shaare Zedek Medical Center, affiliated with the Hebrew University-Hadassah Medical School, Jerusalem, Israel; 7Hematology Department, Your Health SA, Buenos Aires, Argentina; 8Medicina Metabolica Hereditaria, Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Zaragoza, Spain; 9Grupo de Estudio de Enfermedades Hematologıcas y Metabolicas, Hospital Universitario Miguel Servet, Zaragoza, Spain; 10Pediatric Gastroenterology Department, King Edward Memorial Hospital Research Centre, Pune, India; 11Department of Biomedical, Industrial, & Human Factors Engineering, Wright State University, Dayton, Ohio; 12Biostatistics & Statistical Programming Department, Shire, Lexington, Massachusetts; 13Rare Disease Unit, Shire, Lexington, Massachusetts Conflicts of interest: DAH has received consultancy fees, travel and research grants, and honoraria for speaking from Shire, Genzyme, Protalix Biotherapeu- tics, and Amicus. EAL has received honoraria for traveling and participation in advisory boards from Shire and Genzyme. DEG and MK have no competing interests to declare. AM receives consulting fees from Shire, and his institution has received unrestricted research grants from Shire. DE currently receives travel expenses and honoraria for presentations at professional meetings from Shire. IK has received honoraria from Shire. PG has received consultancy fees from Shire, Genzyme, Protalix Biotherapeutics, and Actelion. AB’s institution received a research grant from Shire for a study in patients with type 3 Gaucher disease. TNH is a consultant to Shire. NW is an employee of Shire. EC is a former employee of Shire. AZ receives consultancy fees from Protalix Biotherapeu- tics; has options in Protalix Biotherapeutics and is a member of its Scientific Advisory Board; receives honoraria from Shire, Genzyme/Sanofi, and Pfizer; and his institution receives support from Genzyme for participation in the International Collaborative Gaucher Group Gaucher Registry and from Shire for partici- pation in the Gaucher Outcome Survey. *Correspondence to: Derralynn A. Hughes, Department of Haematology, Royal Free London NHS Foundation Trust, University College London, Rowland Hill Street, London NW3 2PF, UK. E-mail: [email protected] Contract grant sponsor: Shire. Received for publication: 12 December 2014; Revised: 20 February 2015; Accepted: 12 March 2015 Am. J. Hematol. 90:584–591, 2015. Published online: 19 March 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/ajh.24012 VC 2015 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. 584 American Journal of Hematology, Vol. 90, No. 7, July 2015 doi:10.1002/ajh.24012 RESEARCH ARTICLE Velaglucerase alfa long-term treatment for GD1: Phase III data GD registries [3–5]. There is, however, also a need for clinical trial result was also positive, the investigator was to contact the Shire medical monitor evidence for long-term drug efficacy and safety, and this should to determine the appropriate course of action. Efficacy assessments. Blood samples were taken approximately every 3 months include data in pediatric patients. to measure hemoglobin concentration, platelet count, chemokine (CAC motif) Velaglucerase alfa is available as an ERT for type 1 GD. Two ligand 18 (CCL18) level, and chitotriosidase activity, and blood samples were taken randomized, parallel-group phase III trials of velaglucerase alfa were yearly for type I collagen telopeptides N- and C-terminal cross-links (NTx and conducted between 2007 and 2009 in treatment-na€ıve patients, CTx; markers of bone turnover). CCL18 and chitotriosidase were measured accord- including children: study identifiers TKT032 (a parallel assessment of ing to the methods described by Boot et al. [11] and Aguilera et al. [12], respec- tively. CTx and NTx were measured using an enzyme-linked immunosorbent assay. two doses) and HGT-GCB-039 (a noninferiority study comparing Patients underwent quantitative abdominal magnetic resonance imaging at velaglucerase alfa with imiglucerase). No patient discontinued from yearly intervals to assess their spleen and liver volumes. Organ volumes were meas- these studies because of an adverse event (AE), and improvements
Recommended publications
  • Ten Years of the Hunter Outcome Survey (HOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry Joseph Muenzer1, Simon A
    Muenzer et al. Orphanet Journal of Rare Diseases (2017) 12:82 DOI 10.1186/s13023-017-0635-z REVIEW Open Access Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry Joseph Muenzer1, Simon A. Jones2, Anna Tylki-Szymańska3, Paul Harmatz4, Nancy J. Mendelsohn5,6, Nathalie Guffon7, Roberto Giugliani8, Barbara K. Burton9, Maurizio Scarpa10,11, Michael Beck12, Yvonne Jangelind13, Elizabeth Hernberg-Stahl14, Maria Paabøl Larsen15,17, Tom Pulles16,18 and David A. H. Whiteman15* Abstract Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease- specific treatment is available in the form of enzyme replacement therapy with intravenous idursulfase (Elaprase®, Shire). Since 2005, the Hunter Outcome Survey (HOS) has collected real-world, long-term data on the safety and effectiveness of this therapy, as well as the natural history of MPS II. Individuals with a confirmed diagnosis of MPS II who are untreated or who are receiving/have received treatment with idursulfase or bone marrow transplant can be enrolled in HOS. A broad range of disease- and treatment-related information is captured in the registry and, over the past decade, data from more than 1000 patients from 124 clinics in 29 countries have been collected. Evidence generated from HOS has helped to improve our understanding of disease progression in both treated and untreated patients and has extended findings from the formal clinical trials of idursulfase. As a long-term, global, observational registry, various challenges relating to data collection, entry, and analysis have been encountered.
    [Show full text]
  • Publications in Scientific Journals (Peer Reviewed) 1
    Last Updated July 2020 Publications in Scientific Journals (Peer Reviewed) 1. Eisengart JB, King KE, Shapiro EG, Whitley CB, Muenzer J. The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome. Mol Genet Metab Rep. 2019 Dec 20;22:100549. PMID: 32055445 2. Viskochil D, Clarke LA, Bay L, Keenan H, Muenzer J, Guffon N. Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry. Am J Med Genet A. 2019 Dec;179(12):2425-2432. PMID: 31639289 3. Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV, Okuyama T, Viskochil D, Whitley CB, Wijburg FA, Muenzer J. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin Genet. 2019 Clin Genet. 2019 Oct;96(4):281-289. PMID: 31194252 4. Taylor JL, Clinard K, Powell CM, Rehder C, Young SP, Bali D, Beckloff SE, Gehtland LM, Kemper AR, Lee S, Millington D, Patel HS, Shone SM, Woodell C, Zimmerman SJ, Bailey DB Jr, Muenzer J. The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening. J Pediatr. 2019 Aug;211:193-200. PMID: 31133280 5. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI, Jester A, Jones SA, Karsli C, Mackenzie W, Marinho DR, McFadyen A, McGill J, Mitchell JJ, Muenzer J, Okuyama T, Orchard PJ, Stevens B, Thomas S, Walker R, Wynn R, Giugliani R, Harmatz P, Hendriksz C, Scarpa M; MPS Consensus Programme Steering Committee; MPS Consensus Programme Co-Chairs.
    [Show full text]
  • Enzyme Replacement Therapy Srx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 03/15/2017 10/04/2016 Policy Name Policy Number Enzyme Replacement Therapy SRx-0019 Policy Type ☒ Medical ☐ Administrative ☐ Payment Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Specialty Drug Benefit Document
    Louisiana Healthcare Connections Specialty Drug Benefit ouisiana Healthcare Connections provides coverage of a number of specialty drugs. All specialty drugs, such as biopharmaceuticals and injectables, require a prior authorization (PA) to be approved for L payment by Louisiana Healthcare Connections. PA requirements are programmed specific to the drug. Since the list of specialty drugs changes over time due to new drug arrivals and other market conditions, it is important to contact Provider Services at 1-866-595-8133 or check the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com for updates to this benefit. Requests for specialty drugs can be submitted to Louisiana Healthcare Connections by filling out the Medication Prior Authorization Form that is available on the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com and faxing the request as instructed on the form. Louisiana Healthcare Connections members can receive the specialty drugs they require at any outpatient pharmacy enrolled in our pharmacy network that can supply specialty drugs. Providers that wish to have drugs distributed by a SPECIALTY PHARMACY should FAX the request to 1-866-399-0929 for review. If a provider wishes to dispense a specialty drug from OFFICE STOCK, the provider should FAX the request to Louisiana Healthcare Connections at 1-877-401-8172 for review. BRAND NAME INGREDIENTS SPECIAL INSTRUCTIONS ACTEMRA TOCILIZUMAB ACTHAR HP CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA-1B ADAGEN PEGADEMASE BOVINE Limited Distribution
    [Show full text]
  • Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic
    DOI 10.2478/v10219-012-0001-0 ACTA FACULTATIS PHARMACEUTICAE UNIVERSITATIS COMENIANAE Supplementum VI 2012 ORPHAN DRUGS USED FOR TREATMENT IN PEDIATRIC PATIENTS IN THE SLOVAK REPUBLIC 1Foltánová, T. – 2Konečný, M. – 3Hlavatá, A. –.4Štepánková, K. 5Cisárik, F. 1Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology 2Department of Clinical Genetics, St. Elizabeth Cancer Institute, Bratislava 32nd Department of Pediatrics, UniversityChildren'sHospital, Bratislava 4Slovak Cystic Fibrosis Association, Košice 5Department of Medical Genetics, Faculty Hospital, Žilina Due to the enormous success of scientific research in the field of paediatric medicine many once fatal children’s diseases can now be cured. Great progress has also been achieved in the rehabilitation of disabilities. However, there is still a big group of diseases defined as rare, treatment of which has been traditionally neglected by the drug companies mainly due to unprofitability. Since 2000 the treatment of rare diseases has been supported at the European level and in 2007 paediatric legislation was introduced. Both decisions together support treatment of rare diseases in children. In this paper, we shortly characterise the possibilities of rare diseases treatment in children in the Slovak republic and bring the list of orphan medicine products (OMPs) with defined dosing in paediatrics, which were launched in the Slovak market. We also bring a list of OMPs with defined dosing in children, which are not available in the national market. This incentive may help in further formation of the national plan for treating rare diseases as well as improvement in treatment options and availability of rare disease treatment in children in Slovakia.
    [Show full text]
  • September 2017 ~ Resource #330909
    −This Clinical Resource gives subscribers additional insight related to the Recommendations published in− September 2017 ~ Resource #330909 Medications Stored in the Refrigerator (Information below comes from current U.S. and Canadian product labeling and is current as of date of publication) Proper medication storage is important to ensure medication shelf life until the manufacturer expiration date and to reduce waste. Many meds are recommended to be stored at controlled-room temperature. However, several meds require storage in the refrigerator or freezer to ensure stability. See our toolbox, Medication Storage: Maintaining the Cold Chain, for helpful storage tips and other resources. Though most meds requiring storage at temperatures colder than room temperature should be stored in the refrigerator, expect to see a few meds require storage in the freezer. Some examples of medications requiring frozen storage conditions include: anthrax immune globulin (Anthrasil [U.S. only]), carmustine wafer (Gliadel [U.S. only]), cholera (live) vaccine (Vaxchora), dinoprostone vaginal insert (Cervidil), dinoprostone vaginal suppository (Prostin E2 [U.S.]), varicella vaccine (Varivax [U.S.]; Varivax III [Canada] can be stored in the refrigerator or freezer), zoster vaccine (Zostavax [U.S.]; Zostavax II [Canada] can be stored in the refrigerator or freezer). Use the list below to help identify medications requiring refrigerator storage and become familiar with acceptable temperature excursions from recommended storage conditions. Abbreviations: RT = room temperature Abaloparatide (Tymlos [U.S.]) Aflibercept (Eylea) Amphotericin B (Abelcet, Fungizone) • Once open, may store at RT (68°F to 77°F • May store at RT (77°F [25°C]) for up to Anakinra (Kineret) [20°C to 25°C]) for up to 30 days.
    [Show full text]
  • Understanding Elaprase® (Idursulfase) Therapy
    UNDERSTANDING ELAPRASE® (IDURSULFASE) THERAPY: A guide for Hunter syndrome (MPS II) patients and their families Important Safety Information Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE therapy. Patients who have experienced anaphylactic reactions may require prolonged observation. Symptoms of anaphylaxis include difficulty breathing, low blood pressure, hives, and/or swelling of the throat and tongue. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions.1 Please see the accompanying full Prescribing Information, including the Boxed Warning. CONTENTS ELAPRASE® (IDURSULFASE): HOW ELAPRASE® 04 A TREATMENT OPTION FOR 10 (IDURSULFASE) IS HUNTER SYNDROME (MPS II) ADMINISTERED Introduction to ELAPRASE Indication and usage ONEPATH® PRODUCT 11 SUPPORT SERVICES How can OnePath help ® ELAPRASE (IDURSULFASE): eligible patients? 06 THE FIRST AND ONLY ENZYME REPLACEMENT THERAPY (ERT) How to enroll in OnePath FOR HUNTER SYNDROME AVAILABLE IN THE USA FREQUENTLY ASKED Indication and supporting 12 QUESTIONS ABOUT clinical trial efficacy data ELAPRASE® (IDURSULFASE) Adverse reactions (side effects) TALK WITH YOUR HEALTHCARE 14 PROVIDER ABOUT ELAPRASE® IMPORTANT SAFETY (IDURSULFASE) 08 INFORMATION Hypersensitivity reactions including anaphylaxis Risk of hypersensitivity, serious adverse reactions and antibody development in Hunter syndrome patients with severe genetic mutations Risk of acute respiratory complications Please see the accompanying full Prescribing Information, including theRisk Boxed of acute Warning. cardiorespiratory 3 failure ELAPRASE® (idursulfase): A treatment option for Hunter syndrome (MPS II) As you know, living with Hunter syndrome (mucopolysaccharidosis II, MPS II), can be a challenge. For those with Hunter syndrome and their families, each day presents new opportunities to learn more about this genetic disorder and the ways in which it can be managed.
    [Show full text]
  • Biologics and Biosimilars: Background and Key Issues
    Biologics and Biosimilars: Background and Key Issues (name redacted) Specialist in Biomedical Policy September 7, 2016 Congressional Research Service 7-.... www.crs.gov R44620 Biologics and Biosimilars: Background and Key Issues Summary A biological product, or biologic, is a preparation, such as a drug or a vaccine, that is made from living organisms. Compared with conventional chemical drugs, biologics are relatively large and complex molecules. They may be composed of proteins (and/or their constituent amino acids), carbohydrates (such as sugars), nucleic acids (such as DNA), or combinations of these substances. Biologics may also be cells or tissues used in transplantation. A biosimilar, sometimes referred to as a follow-on biologic, is a therapeutic drug that is similar but not structurally identical to the brand-name biologic made by a pharmaceutical or biotechnology company. In contrast to the relatively simple structure and manufacture of chemical drugs, biosimilars, with their more complex nature and method of manufacture, will not be identical to the brand-name product, but may instead be shown to be highly similar. The Food and Drug Administration (FDA) regulates both biologics and chemical drugs. Biologics and biosimilars frequently require special handling (such as refrigeration) and processing to avoid contamination by microbes or other unwanted substances. Also, they are usually administered to patients via injection or infused directly into the bloodstream. For these reasons, biologics often are referred to as specialty drugs. The cost of specialty drugs, including biologics, can be extremely high. In April 2006, the European Medicines Agency (EMA) authorized for marketing in Europe the first biosimilar product, Omnitrope, a human growth hormone.
    [Show full text]
  • Translating Rare-Disease Therapies Into Improved Care for Patients and Families
    © American College of Medical Genetics and Genomics REVIEW Open Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Beth K. Potter, PhD1,2, Sara D. Khangura, BA1, Kylie Tingley, BSc1, Pranesh Chakraborty MD, FRCPC2,3 and Julian Little, PhD1; in collaboration with the Canadian Inherited Metabolic Diseases Research Network There is a need for research to understand and improve health sys- hold the most promise for addressing priorities such as minimizing tems for rare diseases in order to ensure that new, efficacious thera- bias, accounting for cointerventions, identifying long-term impacts, pies developed through basic and early translational science lead to and considering clinical heterogeneity. To effectively engage with real benefits for patients. Such research must (i) focus on appropriate stakeholders, a knowledge exchange infrastructure is needed to foster­ patient-oriented outcomes, (ii) include robust study designs that can collaboration among patients with rare diseases and their families, accommodate real-world decision priorities, and (iii) involve effec- health-care providers, researchers, and policy decision makers. A key tive stakeholder-engagement strategies. For transformative therapies, priority for these groups must be collaboration toward a shared under- study outcomes will need to shift toward longer-term goals in rec- standing of the outcomes that are of most relevance to the facilitation ognition of success in preventing catastrophic outcomes. For incre- of patient-centered care. mental therapies, outcomes should be selected in recognition of the Genet Med advance online publication 9 April 2015 impact of care on quality of life for patients and families.
    [Show full text]
  • Enzyme Replacement LSD Combined Policy
    MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 02/15/2016 11/17/2015 Policy Name Policy Number Enzyme Replacement Therapy and Agents SRx-0019 Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures. Medical Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Shire Collaboration Brings Validation to Armagen's Drug-Delivery Technology
    Shire Collaboration Brings Validation to ArmaGen’s Drug-Delivery Technology By Joseph Haas July 23, 2014 Audience Reach: 45,000 Shire PLC has signed on as the first collaboration with the privately held ArmaGen Technologies Inc., and the work on the specialty pharma’s Hunter syndrome drug Elaprase (idursulfase) could be a valuable validation of ArmaGen’s experimental blood-brain barrier drug- delivery technology. Based on the research of University of California, Los Angeles professor William Pardridge, ArmaGen obtained $17 million in Series A funding in November 2012, with Shire joining the venture arms of Boehringer Ingelheim GMBH, Takeda Pharmaceutical Co. Ltd. and Mitsui & Co. Ltd. in the round [See Deal]. It was clear early on, ArmaGen CEO James Callaway said in an interview, that Shire wanted in on the ground floor of a technology that could enable its Hunter syndrome therapy to address central nervous system symptoms as well as the systemic manifestations it already helped with. “From my interactions with them, Shire clearly wanted a front-row seat to evaluate the technology to deliver Elaprase across the blood-brain barrier,” the executive noted. “From that privileged position, for which they paid equity dollars, they got an opportunity to see the compelling data we’ve been generating prior to the Series A and since, and became motivated to invest more deeply in ArmaGen.” Under the transaction announced July 23, Shire obtains a worldwide license to AGT-182, a late preclinical-stage asset that will fuse the iduronate-2-sulfatase enzyme – which Elaprase replenishes in Hunter syndrome sufferers – with an antibody attracted to the blood-brain barrier’s insulin receptor.
    [Show full text]